Are there Serious Allegations against a Pfizer Supplier?


A subcontractor to the pharmaceutical company is accused of committing multiple violations during clinical trials of Pfizer’s coronavirus vaccine.

Covid-19 Vaccine Found To Have Numerous Flaws

Pfizer was hit hard. One of its subcontractors, a laboratory, is facing serious allegations of committing numerous errors during clinical trials of the Covid-19 vaccine developed by the U.S. group. These allegations are made by a former employee, according to an article published Tuesday, Nov. 2, in the British Medical Journal.

The article alleges that the subcontractor, Texas-based Ventavia Group, which specializes in conducting clinical trials and was hired by Pfizer last year to evaluate the efficacy of its vaccine, “falsified data” and also “delayed monitoring side effects.”

Ventavia played only a small role in trials of the vaccine, which Pfizer developed with Germany-based BioNTech. The Texas company conducted tests on about 1,000 people, while the vaccine was studied in a total of about 44,000 people worldwide.

These trials, which showed particularly high efficacy, led to the vaccine being approved in many countries, including the United States and the European Union.

The main source of the BMJ article is a former Ventavia employee, Brook Jackson, who worked there for fourteen days during the Pfizer/BioNTech vaccine trials before being fired. She says she experienced many failures. Among other things, she accuses Ventavia of interfering with the double-blind allocation of the vaccine through inconsistencies in labeling.

No Comment from the FDA or Pfizer

This process is essential to assess the effectiveness of a treatment compared to a placebo. This ensures that neither patients nor caregivers know whether it is one or the other. Brook Jackson cites other deficiencies, such as the vaccines not being stored at the correct temperature, and says she reported them to the U.S. Food and Drug Administration, which noted her report but did not follow up.

The FDA declined to comment on the case, but assured the report of its “full confidence in the data that led to the approval of the Pfizer/BioNTech vaccine.” According to another anonymous source cited by the BMJ, Pfizer initiated a review of Ventavia after the company was informed of “problems” with the conduct of the trials. Neither Pfizer nor Ventavia immediately responded to AFP’s inquiries.